--- title: "Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286417192.md" datetime: "2026-05-14T12:32:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286417192.md) - [en](https://longbridge.com/en/news/286417192.md) - [zh-HK](https://longbridge.com/zh-HK/news/286417192.md) --- # Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.14, beating the estimate of USD -0.326. EBIT: As of FY2026 Q1, the actual value is USD -16.04 M. #### Net Income (Loss) Candel Therapeutics, Inc. reported a net loss of - $8,861 thousand for the three months ended March 31, 2026, compared to a net income of $7,379 thousand for the same period in 2025 . #### Operating Expenses Total operating expenses increased to $16,284 thousand for the three months ended March 31, 2026, from $8,130 thousand for the three months ended March 31, 2025 . #### Research and Development (R&D) Expenses R&D expenses rose to $9,840 thousand for the three months ended March 31, 2026, an increase of $5,824 thousand from $4,016 thousand in the prior year period . This increase was primarily driven by a $3,589 thousand rise in clinical development costs for aglatimagene programs and a $1,966 thousand increase in employee-related expenses . #### General and Administrative (G&A) Expenses G&A expenses increased to $6,444 thousand for the three months ended March 31, 2026, up $2,330 thousand from $4,114 thousand in the prior year period . This was mainly due to a $1,207 thousand increase in commercial readiness costs and a $650 thousand increase in employee-related expenses . #### Loss from Operations Loss from operations increased to - $16,284 thousand for the three months ended March 31, 2026, compared to - $8,130 thousand for the same period in 2025 . #### Other Income (Expense) - Grant income was $22 thousand for the three months ended March 31, 2026, up from $0 thousand in 2025 . - Interest income increased to $1,322 thousand for the three months ended March 31, 2026, from $934 thousand in 2025, due to a higher cash equivalents balance . - Interest expense increased to - $1,564 thousand for the three months ended March 31, 2026, from - $306 thousand in 2025, primarily due to a higher outstanding balance on the term loan . - Change in fair value of warrant liabilities resulted in a decrease of $7,643 thousand for the three months ended March 31, 2026, compared to a decrease of $14,881 thousand in 2025, influenced by changes in stock price, contractual term, and volatility . #### Cash Flow - Net cash used in operating activities was - $18,037 thousand for the three months ended March 31, 2026, compared to - $8,616 thousand for the same period in 2025 . - Net cash used in investing activities was - $675 thousand for the three months ended March 31, 2026, primarily for fixed asset purchases, compared to - $3 thousand in 2025 . - Net cash provided by financing activities was $93,815 thousand for the three months ended March 31, 2026, mainly from net proceeds from the 2026 Follow-On Offering . This contrasts with - $1,870 thousand used in financing activities in 2025, which included principal payments on a term loan partially offset by proceeds from option exercises and common stock sales . #### Liquidity and Capital Resources As of March 31, 2026, Candel Therapeutics, Inc. had cash and cash equivalents of $194.8 million and total debt of $47.5 million, with an accumulated deficit of $239.2 million . The company expects its existing cash and cash equivalents to fund operations and capital expenditures into the first quarter of 2028 . Substantial additional funding will be required for commercialization of aglatimagene in prostate cancer, advancing the phase 3 NSCLC trial, and further development of linoserpaturev . #### Outlook and Strategy Candel Therapeutics, Inc. plans to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026 and expects to present supportive data in May 2026 and Q3 2026 . The company intends to initiate a pivotal phase 3 clinical trial for aglatimagene in metastatic, non-squamous NSCLC in the second quarter of 2026, which the FDA has indicated could serve as a registrational study . For linoserpaturev, an IND has been cleared for a potential future randomized controlled phase 2 study in recurrent glioblastoma, with mature mOS data expected in Q4 2026 . ### Related Stocks - [CADL.US](https://longbridge.com/en/quote/CADL.US.md) ## Related News & Research - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Atrium Therapeutics Reports First Quarter 2026 Financial Results | RNA Stock News](https://longbridge.com/en/news/286465472.md) - [Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M](https://longbridge.com/en/news/286430906.md) - [Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update | AURX Stock News](https://longbridge.com/en/news/286469940.md) - [BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update | BCLI Stock News](https://longbridge.com/en/news/286606968.md)